JP2014530631A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014530631A5 JP2014530631A5 JP2014537601A JP2014537601A JP2014530631A5 JP 2014530631 A5 JP2014530631 A5 JP 2014530631A5 JP 2014537601 A JP2014537601 A JP 2014537601A JP 2014537601 A JP2014537601 A JP 2014537601A JP 2014530631 A5 JP2014530631 A5 JP 2014530631A5
- Authority
- JP
- Japan
- Prior art keywords
- sucrose solution
- arsine
- dihydroquercetin
- glycyrrhizin
- sid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- RBFQJDQYXXHULB-UHFFFAOYSA-N arsane Chemical compound [AsH3] RBFQJDQYXXHULB-UHFFFAOYSA-N 0.000 claims description 6
- CXQWRCVTCMQVQX-LSDHHAIUSA-N (+)-taxifolin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC=C(O)C(O)=C1 CXQWRCVTCMQVQX-LSDHHAIUSA-N 0.000 claims description 4
- 239000004378 Glycyrrhizin Substances 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- -1 dihydrochalcone glucoside Chemical class 0.000 claims description 4
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims description 4
- 229960004949 glycyrrhizic acid Drugs 0.000 claims description 4
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims description 4
- 235000019410 glycyrrhizin Nutrition 0.000 claims description 4
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 4
- RMLYXMMBIZLGAQ-UHFFFAOYSA-N (-)-monatin Natural products C1=CC=C2C(CC(O)(CC(N)C(O)=O)C(O)=O)=CNC2=C1 RMLYXMMBIZLGAQ-UHFFFAOYSA-N 0.000 claims description 2
- WRPAFPPCKSYACJ-ZBYJYCAASA-N (2r,3r,4s,5s,6r)-2-[[(2r,3s,4s,5r,6r)-6-[[(3s,8r,9r,10s,11r,13r,14s,17r)-17-[(5r)-5-[(2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2r,3s,4r,5r,6s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-hydroxy-6-methylheptan-2-yl]-11-hydrox Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H](CCC(C)[C@@H]1[C@]2(C[C@@H](O)[C@@]3(C)[C@@H]4C(C([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]6[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O6)O)O5)O)CC4)(C)C)=CC[C@@H]3[C@]2(C)CC1)C)C(C)(C)O)[C@H]1O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]1O WRPAFPPCKSYACJ-ZBYJYCAASA-N 0.000 claims description 2
- XJIPREFALCDWRQ-UYQGGQRHSA-N (2r,3r,4s,5s,6r)-2-[[(2r,3s,4s,5r,6s)-3,4-dihydroxy-6-[(3r,6r)-2-hydroxy-6-[(3s,8s,9r,10r,11r,13r,14s,17r)-11-hydroxy-4,4,9,13,14-pentamethyl-3-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,3,7,8,10,11,12,15,16,17-decahydro-1h-cyclop Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@H](CC[C@@H](C)[C@@H]1[C@]2(C[C@@H](O)[C@@]3(C)[C@H]4C(C([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC4)(C)C)=CC[C@H]3[C@]2(C)CC1)C)C(C)(C)O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O XJIPREFALCDWRQ-UYQGGQRHSA-N 0.000 claims description 2
- RMLYXMMBIZLGAQ-HZMBPMFUSA-N (2s,4s)-4-amino-2-hydroxy-2-(1h-indol-3-ylmethyl)pentanedioic acid Chemical compound C1=CC=C2C(C[C@](O)(C[C@H](N)C(O)=O)C(O)=O)=CNC2=C1 RMLYXMMBIZLGAQ-HZMBPMFUSA-N 0.000 claims description 2
- QZOALWMSYRBZSA-PDSBIMDKSA-N (3r,5r,8r,9r,10r,13s,14r)-3-[(2r,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-10,13-dimethyl-17-[(1s)-1-[(2r,5s,6r)-5-methyl-6-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1C[C@H]2C(=O)C[C@@H]3[C@H]4CCC([C@]4(CC[C@H]3[C@@]2(C)CC1)C)[C@H](C)[C@@H]1O[C@H](O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)[C@@H](C)CC1)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O QZOALWMSYRBZSA-PDSBIMDKSA-N 0.000 claims description 2
- NNXQSUSEFPRCRS-YCKMUKMSSA-N 3-[(3S,3aR,4R,5aR,6S,7S,9aR,9bR)-3-[(E,2S)-2,6-dihydroxy-6-methylhept-4-en-2-yl]-6,9a,9b-trimethyl-7-prop-1-en-2-yl-4-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-1,2,3,3a,4,5,5a,7,8,9-decahydrocyclopenta[a]naphthalen-6-yl]propanoic acid Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1[C@@H]2[C@@H]([C@@](C)(O)C\C=C\C(C)(C)O)CC[C@@]2(C)[C@]2(C)CC[C@@H](C(C)=C)[C@](C)(CCC(O)=O)[C@H]2C1 NNXQSUSEFPRCRS-YCKMUKMSSA-N 0.000 claims description 2
- GLLUYNRFPAMGQR-UHFFFAOYSA-N Glycyphyllin Natural products OC1C(O)C(O)C(C)OC1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 GLLUYNRFPAMGQR-UHFFFAOYSA-N 0.000 claims description 2
- QZOALWMSYRBZSA-UHFFFAOYSA-N Osladin Natural products C1CC(C)C(OC2C(C(O)C(O)C(C)O2)O)OC1C(C)C(C1(CCC2C3(C)CC4)C)CCC1C2CC(=O)C3CC4OC1OC(CO)C(O)C(O)C1OC1OC(C)C(O)C(O)C1O QZOALWMSYRBZSA-UHFFFAOYSA-N 0.000 claims description 2
- OFFJUHSISSNBNT-UHFFFAOYSA-N Polypodoside A Natural products C1CC(C)C(OC2C(C(O)C(O)C(C)O2)O)OC1C(C)C(C1(CCC2C3(C)CC4)C)CCC1C2=CC(=O)C3CC4OC1OC(CO)C(O)C(O)C1OC1OC(C)C(O)C(O)C1O OFFJUHSISSNBNT-UHFFFAOYSA-N 0.000 claims description 2
- XSDXQNVJNSCZNC-UHFFFAOYSA-N [5,7-dihydroxy-2-(4-methoxyphenyl)-4-oxo-2,3-dihydrochromen-3-yl] acetate Chemical compound C1=CC(OC)=CC=C1C1C(OC(C)=O)C(=O)C2=C(O)C=C(O)C=C2O1 XSDXQNVJNSCZNC-UHFFFAOYSA-N 0.000 claims description 2
- 229930193947 albiziasaponin Natural products 0.000 claims description 2
- JOKKBOSZTVHKSH-UHFFFAOYSA-N baiyunoside Natural products CC12CCC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)CO3)O)C(C)(C)C1CCC(C)=C2CCC=1C=COC=1 JOKKBOSZTVHKSH-UHFFFAOYSA-N 0.000 claims description 2
- 108010010165 curculin Proteins 0.000 claims description 2
- XCGZWJIXHMSSQC-UHFFFAOYSA-N dihydroquercetin Natural products OC1=CC2OC(=C(O)C(=O)C2C(O)=C1)c1ccc(O)c(O)c1 XCGZWJIXHMSSQC-UHFFFAOYSA-N 0.000 claims description 2
- GLLUYNRFPAMGQR-PPNXFBDMSA-N glycyphyllin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 GLLUYNRFPAMGQR-PPNXFBDMSA-N 0.000 claims description 2
- 229930191869 mogroside IV Natural products 0.000 claims description 2
- OKGRRPCHOJYNKX-UHFFFAOYSA-N mogroside IV A Natural products C1CC2(C)C3CC=C(C(C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)C(CO)O5)O)O4)O)CC4)(C)C)C4C3(C)C(O)CC2(C)C1C(C)CCC(C(C)(C)O)OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C(O)C1O OKGRRPCHOJYNKX-UHFFFAOYSA-N 0.000 claims description 2
- WRPAFPPCKSYACJ-UHFFFAOYSA-N mogroside IV E Natural products C1CC2(C)C3CC=C(C(C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)C(CO)O5)O)O4)O)CC4)(C)C)C4C3(C)C(O)CC2(C)C1C(C)CCC(C(C)(C)O)OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O WRPAFPPCKSYACJ-UHFFFAOYSA-N 0.000 claims description 2
- OHLBTNZSOHMDGY-JNMXELLOSA-N mukurozioside IIb Natural products O(C/C(=C\CC/C(=C\CC/C(=C\CO[C@H]1[C@H](O[C@@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](O)[C@@H](CO)O1)/C)/C)/C)[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](O)[C@@H](CO)O1 OHLBTNZSOHMDGY-JNMXELLOSA-N 0.000 claims description 2
- ALAGDBVXZZADSN-UHFFFAOYSA-N pentazine Chemical compound C1=NN=NN=N1 ALAGDBVXZZADSN-UHFFFAOYSA-N 0.000 claims description 2
- 150000003085 polypodoside A derivatives Polymers 0.000 claims description 2
- DMRIOWKDQLGGAP-UHFFFAOYSA-N polypodoside B Natural products C1CC(C)C(OC2C(C(O)C(O)C(C)O2)O)OC1C(C)C(C1(CCC2C3(C)CC4)C)CCC1C2=CC(=O)C3CC4OC1OC(CO)C(O)C(O)C1O DMRIOWKDQLGGAP-UHFFFAOYSA-N 0.000 claims description 2
- DMRIOWKDQLGGAP-FPYDNAILSA-N polypodoside B group Chemical group [C@@H]12CC[C@H]([C@H](C)[C@H]3CC[C@H](C)[C@@H](OC4OC(C)C(O)C(O)C4O)O3)[C@@]1(C)CC[C@H]1C2=CC(=O)[C@H]2C[C@H](CC[C@]12C)OC1OC(CO)C(O)C(O)C1O DMRIOWKDQLGGAP-FPYDNAILSA-N 0.000 claims description 2
- NNXQSUSEFPRCRS-UHFFFAOYSA-N pterocaryoside A Natural products OC1C(O)C(O)C(C)OC1OC1C2C(C(C)(O)CC=CC(C)(C)O)CCC2(C)C2(C)CCC(C(C)=C)C(C)(CCC(O)=O)C2C1 NNXQSUSEFPRCRS-UHFFFAOYSA-N 0.000 claims description 2
- SODWWCZKQRRZTG-UHFFFAOYSA-N pterocaryoside B Natural products OC(=O)CCC1(C)C(C(=C)C)CCC(C2(CCC(C22)C(C)(O)CC=CC(C)(C)O)C)(C)C1CC2OC1OCC(O)C(O)C1O SODWWCZKQRRZTG-UHFFFAOYSA-N 0.000 claims description 2
- XJIPREFALCDWRQ-UHFFFAOYSA-N siamenoside I Natural products C1CC2(C)C3CC=C(C(C(OC4C(C(O)C(O)C(CO)O4)O)CC4)(C)C)C4C3(C)C(O)CC2(C)C1C(C)CCC(C(C)(C)O)OC(C(C(O)C1O)OC2C(C(O)C(O)C(CO)O2)O)OC1COC1OC(CO)C(O)C(O)C1O XJIPREFALCDWRQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000000892 thaumatin Substances 0.000 claims description 2
- 235000010436 thaumatin Nutrition 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 4
- 229930006000 Sucrose Natural products 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 239000005720 sucrose Substances 0.000 claims 4
- GHBNZZJYBXQAHG-KUVSNLSMSA-N (2r,3r,4s,5s,6r)-2-[[(2r,3s,4s,5r,6r)-6-[[(3s,8s,9r,10r,11r,13r,14s,17r)-17-[(2r,5r)-5-[(2s,3r,4s,5s,6r)-4,5-dihydroxy-3-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@H](CC[C@@H](C)[C@@H]1[C@]2(C[C@@H](O)[C@@]3(C)[C@H]4C(C([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]6[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O6)O)O5)O)CC4)(C)C)=CC[C@H]3[C@]2(C)CC1)C)C(C)(C)O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GHBNZZJYBXQAHG-KUVSNLSMSA-N 0.000 claims 1
- 239000001183 FEMA 4495 Substances 0.000 claims 1
- 239000001689 FEMA 4674 Substances 0.000 claims 1
- CWBZAESOUBENAP-QVNVHUMTSA-N Naringin dihydrochalcone Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C(O)C(C(=O)CCC=3C=CC(O)=CC=3)=C(O)C=2)O[C@H](CO)[C@@H](O)[C@@H]1O CWBZAESOUBENAP-QVNVHUMTSA-N 0.000 claims 1
- 241001092459 Rubus Species 0.000 claims 1
- YWPVROCHNBYFTP-UHFFFAOYSA-N Rubusoside Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC1OC(CO)C(O)C(O)C1O YWPVROCHNBYFTP-UHFFFAOYSA-N 0.000 claims 1
- 229930182647 Trilobatin Natural products 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- PXLWOFBAEVGBOA-UHFFFAOYSA-N dihydrochalcone Natural products OC1C(O)C(O)C(CO)OC1C1=C(O)C=CC(C(=O)CC(O)C=2C=CC(O)=CC=2)=C1O PXLWOFBAEVGBOA-UHFFFAOYSA-N 0.000 claims 1
- 229930182478 glucoside Natural products 0.000 claims 1
- TVJXHJAWHUMLLG-UHFFFAOYSA-N mogroside V Natural products CC(CCC(OC1OC(COC2OC(CO)C(O)C(O)C2OC3OC(CO)C(O)C(O)C3O)C(O)C(O)C1O)C(C)(C)O)C4CCC5(C)C6CC=C7C(CCC(OC8OC(COC9OC(CO)C(O)C(O)C9O)C(O)C(O)C8O)C7(C)C)C6(C)C(O)CC45C TVJXHJAWHUMLLG-UHFFFAOYSA-N 0.000 claims 1
- 229930183085 periandrin Natural products 0.000 claims 1
- YWPVROCHNBYFTP-OSHKXICASA-N rubusoside Chemical compound O([C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YWPVROCHNBYFTP-OSHKXICASA-N 0.000 claims 1
- GSTCPEBQYSOEHV-QNDFHXLGSA-N trilobatin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C=C1O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 GSTCPEBQYSOEHV-QNDFHXLGSA-N 0.000 claims 1
- 239000003623 enhancer Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161550495P | 2011-10-24 | 2011-10-24 | |
| US61/550,495 | 2011-10-24 | ||
| PCT/EP2012/071088 WO2013060746A1 (en) | 2011-10-24 | 2012-10-24 | Compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014530631A JP2014530631A (ja) | 2014-11-20 |
| JP2014530631A5 true JP2014530631A5 (enExample) | 2015-12-17 |
| JP6353364B2 JP6353364B2 (ja) | 2018-07-04 |
Family
ID=47115891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014537601A Active JP6353364B2 (ja) | 2011-10-24 | 2012-10-24 | 組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20140370177A1 (enExample) |
| EP (1) | EP2770843B1 (enExample) |
| JP (1) | JP6353364B2 (enExample) |
| CN (1) | CN104039166B (enExample) |
| BR (1) | BR112014009376B1 (enExample) |
| IN (1) | IN2014CN02970A (enExample) |
| MX (1) | MX354411B (enExample) |
| SG (1) | SG11201401335QA (enExample) |
| WO (1) | WO2013060746A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201418893D0 (en) | 2014-10-23 | 2014-12-10 | Univ Hull | Monolithic body |
| GB201418899D0 (en) | 2014-10-23 | 2014-12-10 | Univ Hull | System for radiopharmaceutical production |
| GB201418897D0 (en) | 2014-10-23 | 2014-12-10 | Univ Hull | Methods and apparatus for the analysis of compounds |
| EP3268487B1 (en) * | 2015-03-10 | 2025-02-26 | Rijksuniversiteit Groningen | Methods for the enzymatic modification of steviol glycosides, modified steviol glycosides obtainable thereby, and the use thereof as sweeteners |
| PL3808190T3 (pl) * | 2016-12-30 | 2024-08-26 | Red Bull Gmbh | Kompozycje, zwłaszcza kompozycje słodzące |
| NZ755861A (en) * | 2016-12-30 | 2025-11-28 | Red Bull Gmbh | Sweetening compositions |
| US11076619B2 (en) | 2016-12-30 | 2021-08-03 | Red Bull Gmbh | Sweetening compositions |
| CN116941752A (zh) * | 2017-06-02 | 2023-10-27 | 奇华顿股份有限公司 | 组合物 |
| US20200367542A1 (en) | 2017-10-23 | 2020-11-26 | Symrise Ag | Aroma composition |
| US20200221722A1 (en) * | 2019-01-15 | 2020-07-16 | Kween Foods LLC | Granola butter product and process of making a granola butter product |
| JP2022547292A (ja) * | 2019-09-05 | 2022-11-11 | フイルメニツヒ ソシエテ アノニム | フラバノン誘導体及び甘味増強剤としてのフラバノン誘導体の使用 |
| WO2021130046A1 (en) * | 2019-12-23 | 2021-07-01 | Firmenich Sa | Triterpene glucuronides and their use as flavor modifiers |
| CA3179775A1 (en) | 2020-04-20 | 2021-10-28 | Givaudan Sa | Compositions |
| GB202007984D0 (en) | 2020-05-28 | 2020-07-15 | Givaudan Sa | Compositions |
| WO2024240572A1 (en) | 2023-05-22 | 2024-11-28 | Givaudan Sa | Dried cocoa pulp composition, consumables and methods |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8293305B2 (en) * | 2005-10-11 | 2012-10-23 | Purecircle Sdn Bhd | Process for manufacturing a sweetener and use thereof |
| EP2047254B1 (en) * | 2006-04-20 | 2015-10-28 | Givaudan SA | Method relating to sweetness enhancement |
| MX2009004344A (es) * | 2006-10-24 | 2009-05-05 | Givaudan Sa | Productos de consumo. |
| US9101161B2 (en) * | 2006-11-02 | 2015-08-11 | The Coca-Cola Company | High-potency sweetener composition with phytoestrogen and compositions sweetened therewith |
| EP2214681B1 (en) * | 2007-12-03 | 2021-10-20 | DSM IP Assets B.V. | Novel nutraceutical compositions containing steviol and uses thereof |
| CN101220062A (zh) * | 2008-01-23 | 2008-07-16 | 石任兵 | 一种同时制备甜菊苷和莱鲍迪苷a的方法 |
| SG178376A1 (en) * | 2009-09-04 | 2012-03-29 | Redpoint Bio Corp | Sweetness enhancers including rebaudioside a or d |
-
2012
- 2012-10-24 BR BR112014009376-8A patent/BR112014009376B1/pt active IP Right Grant
- 2012-10-24 IN IN2970CHN2014 patent/IN2014CN02970A/en unknown
- 2012-10-24 US US14/352,223 patent/US20140370177A1/en active Pending
- 2012-10-24 CN CN201280052169.0A patent/CN104039166B/zh active Active
- 2012-10-24 MX MX2014004694A patent/MX354411B/es active IP Right Grant
- 2012-10-24 SG SG11201401335QA patent/SG11201401335QA/en unknown
- 2012-10-24 JP JP2014537601A patent/JP6353364B2/ja active Active
- 2012-10-24 EP EP12780165.2A patent/EP2770843B1/en active Active
- 2012-10-24 WO PCT/EP2012/071088 patent/WO2013060746A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014530631A5 (enExample) | ||
| BR112014031068A2 (pt) | derivados piridinona e piridazinona | |
| EA200870216A1 (ru) | Амидо соединения и их применение в качестве лекарственных средств | |
| AR064149A1 (es) | Sal fumarato de (alfa s , beta r)-6 bromo- alfa-[ 2(dimetilamino ) etil)-2- metoxi - alfa-1-naftalenil- beta- fenil-3- quinolinaetanol | |
| BR112014009376A2 (pt) | composições | |
| DE602007011302D1 (de) | Ligustilid zur behandlung von erkrankungen des zentralen nervensystems | |
| NO20074559L (no) | O-Desmetylvenlafaxin og bazedoxifen kombinasjonsprodukt og anvendelser derav | |
| BR112013011882A2 (pt) | fórmula nutricional adaptada à idade com densidade calórica particularmente adaptada para bebês e crianças | |
| FR2925326B1 (fr) | Utilisation d'un hydrolysat de mais en tant que principe actif activateur de la synthese des aquaporines | |
| EP2898923A3 (en) | Isoflavones for regulating sirtuin gene expression | |
| ATE528290T1 (de) | Spiroindolinon-derivate | |
| AU2010323104A8 (en) | Sialochimeric compounds | |
| TR200900881A2 (tr) | Tadı ve kokusu maskelenmiş stabil farmasötik bileşimler | |
| BR112012026373A2 (pt) | derivados de ditiinopiridazinodiona | |
| JP2013082696A5 (enExample) | ||
| Forbes et al. | COMPASS collaborative research Strand 3: Research into practice: implementing a complex psychoeducational intervention to promote early presentation in older women with breast cancer | |
| Durrheim et al. | Guest Editorial: Preparing for the inevitable—an influenza pandemic | |
| Phelps et al. | Sex Differences In The Alveolar Macrophage Proteome In Response To Treatment With Exogenous Surfactant Protein-A | |
| TH106485A (th) | วิธีเพื่อป้องกันการใช้คอร์ติโคสเตียรอยด์ | |
| Schiffrin | SY 15-1 MECHANISM OF ENDOTHELIN-1 REGULATION IN HYPERTENSION: THE ROLE OF ENDOTHELIN TYPE A RECEPTORS | |
| Jones et al. | A programme of care in palliative day care | |
| NO20085189L (no) | 2-alkoksy-3,4,5-trihydroksy-alkylamid-benzotaizepiner, fremstilling og anvendelse derav sammensetninger inneholdende samme | |
| Råberg | Högskolan i Halmstads miljöarbete-syndliggörande för studenterna | |
| Cantoni et al. | Abandoning Care in Laminar Air Flow (LAF) Units and Routine High Dose Intravenous Immunoglobulines (IVIG) in Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Does Not Increase Mortality and Rate of Infections. | |
| Tauseef et al. | TRPC6 Channel Mediated Calcium Entry Requires RhoA and Myosin Light Chain Kinase To Increase Lung Vascular Permeability. |